Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912065 · ClinicalTrials.gov registry record
Tube Feeding Tolerance After Switch to Peptide Based Formula in Children With Developmental Delay
A clinical trial, sponsored by Société des Produits Nestlé (SPN).
- Completed
- Registry status
- 13
- Enrollment target
NCT02912065: Completed study, sponsored by Société des Produits Nestlé (SPN).
NCT02912065 is a clinical trial that has completed, run by Société des Produits Nestlé (SPN). The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02912065 has completed, sponsored by Société des Produits Nestlé (SPN).
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
A retrospective chart review to assess feeding tolerance in children who had been switched from an intact protein formula to a Peptide based formula due to feeding intolerance in a pediatric facility for the developmentally delayed.
Primary Outcome
Categorized as no change, tolerance improved, tolerance worsened.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-03 |
What the finished NCT02912065 record still lists
NCT02912065 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02912065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02912065 about?
NCT02912065 is a clinical study titled "Tube Feeding Tolerance After Switch to Peptide Based Formula in Children With Developmental Delay". A retrospective chart review to assess feeding tolerance in children who had been switched from an intact protein formula to a Peptide based formula due to feeding intolerance in a pediatric facility for the developmentally delayed.
What is the current status of trial NCT02912065?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2015-01. Estimated completion is 2015-03.
Who is sponsoring clinical trial NCT02912065?
This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia